Last reviewed · How we verify
Divalproex (DIV) ER
Divalproex inhibits histone deacetylase and enhances GABA neurotransmission, reducing neuronal excitability.
Divalproex inhibits histone deacetylase and enhances GABA neurotransmission, reducing neuronal excitability. Used for Epilepsy (seizure disorders), Bipolar disorder (acute mania), Migraine prophylaxis.
At a glance
| Generic name | Divalproex (DIV) ER |
|---|---|
| Also known as | Depakote ER, valproic Acid |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Drug class | Anticonvulsant / Mood stabilizer |
| Target | GABA synthesis enhancement; histone deacetylase inhibition |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Divalproex is a compound of sodium valproate and valproic acid that works through multiple mechanisms: it increases brain levels of GABA (gamma-aminobutyric acid), an inhibitory neurotransmitter, and inhibits histone deacetylase enzymes. These actions reduce abnormal electrical activity in the brain and stabilize mood. The extended-release (ER) formulation provides sustained drug levels over 24 hours.
Approved indications
- Epilepsy (seizure disorders)
- Bipolar disorder (acute mania)
- Migraine prophylaxis
Common side effects
- Tremor
- Nausea
- Somnolence
- Alopecia (hair loss)
- Weight gain
- Hepatotoxicity
- Pancreatitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |